Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study
MBSR
1 other identifier
interventional
107
1 country
1
Brief Summary
To investigate the efficacy of Mindfulness-based Stress Reduction (MBSR) to improve quality of life, cognition, and mood, as well as to determine the longevity of the treatment response in individuals with Parkinson's disease (PD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2019
CompletedFirst Posted
Study publicly available on registry
June 26, 2019
CompletedStudy Start
First participant enrolled
January 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2024
CompletedResults Posted
Study results publicly available
November 18, 2025
CompletedNovember 18, 2025
November 1, 2025
4.8 years
June 24, 2019
November 5, 2025
November 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Parkinson's Disease Questionnaire-39
Parkinson's disease Quality of Life (PDQ-39); Total Score = 0-156; higher score = worse quality of life.
pre- to post-intervention (0 to 9 weeks)
Secondary Outcomes (2)
Matrix Reasoning Test
pre- to post-intervention (0 to 9 weeks)
State-Trait Anxiety Inventory
pre- to post-intervention (0 to 9 weeks)
Study Arms (2)
Mindfulness Based Stress Reduction (MBSR)
ACTIVE COMPARATORIndividuals with Parkinson's disease were randomly assigned to one of two study arms: MBSR or PSC. The MBSR intervention was based on the standard program developed by Jon Kabat-Zinn (1990). It consisted of weekly 2.5 hours sessions x 8 weeks and one 4-hour retreat during week 7. Due to the COVID-19 pandemic, all MBSR sessions were conducted completely online with randomized groups of 6-9 individuals with PD and were led by a trained instructor who was not involved in the clinical care or assessment of the participants.
Psychoeducational Supportive Care (PSC)
ACTIVE COMPARATORIndividuals with Parkinson's disease were randomly assigned to one of two study arms: MBSR or PSC. PSC is a novel intervention developed by Schiehser and colleagues to serve as a control for MBSR in this trial. PSC was modeled after common support/education groups that provide support and psychoeducation about Parkinson's disease available in the community. PSC consisted of weekly 2.5 hours sessions x 8 weeks and one 4-hour "retreat" during week 7. Due to the COVID-19 pandemic, all sessions were conducted completely online with randomized groups of 6-9 individuals with PD and were led by a trained instructor who was not involved in the clinical care or assessment of the participants.
Interventions
MBSR used in this trial was based on the standard program developed by Jon Kabat-Zinn (1990). It consisted of weekly 2.5 hours sessions x 8 weeks and one 4-hour retreat during week 7. Due to the COVID-19 pandemic, the MBSR sessions were conducted completely online with randomized groups of 6-9 individuals with PD and were led by a trained instructor who was not involved in the clinical care or assessment of the participants.
PSC is a novel intervention developed by Schiehser and colleagues to provide psychoeducation about Parkinson's disease and supportive group care. PSC consisted of weekly 2.5 hours sessions x 8 weeks and one 4-hour "retreat" during week 7. Due to the COVID-19 pandemic, all sessions were conducted completely online with randomized groups of 6-9 individuals with PD and were led by a trained instructor who was not involved in the clinical care or assessment of the participants.
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of PD based on UK Brain Bank Criteria
- years of age or older
You may not qualify if:
- Secondary causes of Parkinsonism (e.g. corticobasal degeneration, progressive supranuclear palsy, drug-induced parkinsonism)
- Other neurological conditions (e.g. stroke)
- Clinical diagnosis of dementia based on any previous neuropsychological testing
- Psychosis, antipsychotic treatment or treatment for substance abuse
- Uncorrected vision or hearing to adequately participate in the intervention
- Prior formal training in MBSR or regular current MBSR practice
- Inability to use a computer or technology for participation
- Active/current suicidal ideation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
VA San Diego Healthcare System
San Diego, California, 92161-0002, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Outcome measures were adjusted and/or modified in order to be administered online due to the COVID-19 pandemic.
Results Point of Contact
- Title
- Dr. Dawn Schiehser, Ph.D.
- Organization
- North Florida/South Georgia VA Healthcare System
Study Officials
- PRINCIPAL INVESTIGATOR
Dawn M. Schiehser, PhD
San Diego Veterans Healthcare System
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Investigator and Assessor are blinded to group assignment.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2019
First Posted
June 26, 2019
Study Start
January 1, 2020
Primary Completion
November 1, 2024
Study Completion
November 1, 2024
Last Updated
November 18, 2025
Results First Posted
November 18, 2025
Record last verified: 2025-11